Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00060086 · ClinicalTrials.gov registry record · NA

Pomegranate Juice in Treating Patients With Recurrent Prostate Cancer

A NA study, sponsored by Jonsson Comprehensive Cancer Center.

Completed
Registry status
NA
Development phase
47
Enrollment target

NCT00060086 is a NA study that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 47 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00060086, a NA study, has completed, sponsored by Jonsson Comprehensive Cancer Center.

COMPLETED
Registry status
NA
Development phase
47 participants
Enrollment target

Study Summary

RATIONALE: Pomegranate juice may contain substances that decrease or slow the rise of prostate-specific antigen (PSA) levels and may be effective in delaying or preventing recurrent prostate cancer. PURPOSE: This phase II trial is studying how well pomegranate juice works in decreasing or slowing the rise of PSA levels in patients who have undergone radiation therapy or surgery for prostate cancer.

Interventions

  • DIETARY_SUPPLEMENT pomegranate juice

Trial Details

FieldValue
Enrollment Target 47 participants
Start Date 2004-11-30
Est. Completion 2021-05-25
Phase NA

Sponsor

Jonsson Comprehensive Cancer Center

321 total trials

What the Registry Record Tells You About NCT00060086

The ClinicalTrials.gov registry entry for NCT00060086 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which pomegranate juice is the first listed.

NCT00060086 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00060086 about?

NCT00060086 is a clinical study titled "Pomegranate Juice in Treating Patients With Recurrent Prostate Cancer". RATIONALE: Pomegranate juice may contain substances that decrease or slow the rise of prostate-specific antigen (PSA) levels and may be effective in delaying or preventing recurrent prostate cancer. PURPOSE: This phase II trial is studying how well pomegranate juice works in decreasing or slowing t...

What is the current status of trial NCT00060086?

This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2004-11-30. Estimated completion is 2021-05-25.

What interventions are being tested in trial NCT00060086?

The interventions under investigation include: pomegranate juice (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT00060086?

This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.